Foresite Capital Management III, LLC - Q3 2018 holdings

$453 Million is the total value of Foresite Capital Management III, LLC's 24 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 18.2% .

 Value Shares↓ Weighting
MYOK SellMyokardia, Inc.$24,274,000
+24.5%
372,300
-5.2%
5.36%
+27.5%
AIMT SellAimmune Therapeutics, Inc.$21,858,000
-4.5%
801,240
-5.9%
4.82%
-2.2%
BPMC SellBlueprint Medicines Corporation$15,612,000
-1.6%
200,000
-20.0%
3.44%
+0.8%
XLRN SellAcceleron Pharma Inc.$14,357,000
+6.2%
250,863
-10.0%
3.17%
+8.8%
SLDB SellSolid Biosciences Inc.$11,223,000
-6.8%
237,884
-29.6%
2.48%
-4.5%
EPZM SellEpizyme, Inc.$9,728,000
-23.7%
917,715
-2.4%
2.15%
-21.8%
AKAOQ SellAchaogen, Inc.$9,474,000
-61.9%
2,374,418
-17.4%
2.09%
-61.0%
VRNA SellVerona Pharma Plcsponsored ads$6,266,000
-8.8%
500,883
-0.4%
1.38%
-6.5%
WVE SellWAVE Life Sciences Ltd.$2,500,000
-12.9%
50,000
-33.3%
0.55%
-10.7%
ExitImmunomedics, Inc.call$0-150,000
-100.0%
-0.76%
ExitImmunomedics, Inc.put$0-150,000
-100.0%
-0.76%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Epizyme, Inc.24Q3 202117.6%
Acceleron Pharma Inc.22Q3 202125.9%
CymaBay Therapeutics, Inc.20Q3 202217.6%
Aerie Pharmaceuticals, Inc.18Q1 202033.5%
Ascendis Pharma A/S17Q3 202247.8%
Alder BioPharmaceuticals, Inc.16Q3 201927.4%
Natera, Inc.16Q3 202221.5%
Aimmune Therapeutics, Inc.16Q3 20198.1%
Verona Pharma PLC.15Q3 202230.0%
WAVE Life Sciences Ltd.15Q2 201920.0%

View Foresite Capital Management III, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2022-11-14
13F-HR2022-08-12
13F-HR2022-05-13
13F-HR2022-02-11
13F-HR2021-11-12
42021-11-03
13F-HR2021-08-16
13F-HR2021-05-17
13F-HR2021-02-16
32021-02-10

View Foresite Capital Management III, LLC's complete filings history.

Compare quarters

Export Foresite Capital Management III, LLC's holdings